## Erika Paolini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5102866/publications.pdf

Version: 2024-02-01

10	226	7	10
papers	citations	h-index	g-index
11	11	11	177 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	MAFLD definition underestimates the risk to develop HCC in genetically predisposed patients. Journal of Internal Medicine, 2022, 291, 374-376.	6.0	8
2	Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Hepatology Communications, 2022, 6, 535-549.	4.3	18
3	TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in InÂVitro Models. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 759-788.	4.5	44
4	Cutting-Edge Therapies and Novel Strategies for Acute Intermittent Porphyria: Step-by-Step towards the Solution. Biomedicines, 2022, 10, 648.	3.2	7
5	Nonalcoholic fatty liver disease or metabolic dysfunctionâ€associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches. European Journal of Clinical Investigation, 2021, 51, e13519.	3.4	32
6	The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation. EBioMedicine, 2021, 65, 103249.	6.1	11
7	Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending?. Metabolism: Clinical and Experimental, 2021, 117, 154708.	3.4	59
8	The rs599839 A>G Variant Disentangles Cardiovascular Risk and Hepatocellular Carcinoma in NAFLD Patients. Cancers, 2021, 13, 1783.	3.7	16
9	Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC. International Journal of Molecular Sciences, 2021, 22, 4173.	4.1	23
10	α-Lipoic Acid Improves Hepatic Metabolic Dysfunctions in Acute Intermittent Porphyria: A Proof-of-Concept Study. Diagnostics, 2021, 11, 1628.	2.6	5